Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

Partial nephrectomy preserves renal function better than radical nephrectomy for complex tumors, especially in younger ...

DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non ...

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have ...

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal ...

The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic ...